Protalix publishes corporate presentation highlighting Elfabrio commercialization and PRX-115 Phase 2 gout study
PLX•Corporate presentation highlights profitability and cash position
Protalix said it highlighted profitability with net income of $22.1 million for the first half of 2026.
Cash and cash equivalents were $40.7 million as of June 30, 2026, with no debt and no warrants.
Total revenues were $53.6 million year to date, including a $25 million Chiesi milestone in the first quarter of 2026.
Elfabrio sales drive second-quarter revenue and PRX-115 study advances
Second-quarter revenue from selling goods rose to $19.8 million, driven by Elfabrio sales.
Protalix also said the PRX-115 Phase 2 trial in uncontrolled gout is enrolling, with topline data targeted for the second half of 2027.
